Federal budget issues
IRA implementation, pharmaceutical access and affordability, 340B, HCV screening, drug pricing and access, HIV, oncology, PAPHA reauthorization, transparency
Medicare & Medicaid payment and coverage issues
Duration: January 1, 2019
to
present
General Issues: Budget/Appropriations , Health Issues , Medicare/Medicaid , Pharmacy
Spending: about $1,680,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Raissa Downs
Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte.
Jennifer Young
Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff, Sen. Cmte. on Finance
Michelle Easton
Chief Health Counsel, Sen. Cmte. on Finance; Staff Dir., Senate Aging Cmte.; Leg. Asst., Congressman Billy Tauzin
Elizabeth Murray
Senior Policy Advisor, Democratic Whip Steny Hoyer; Legislative Asst. for Rep. Mike Thompson, Rep. Bob Matsui, and Senator Bob Graham
Charlotte Ivancic
Leg. Counsel, Sen. Jim DeMint; Health Counsel, Maj. Leader Bill Frist; Counsel and Budget Analyst, House Budget Cmte.; Asst. to the Speaker for Policy, Speaker John Boehner
Pamela Smith
Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Senate HELP Cmte; Staff Dir., Senate HELP Cmte; Counselor to the Asst. AG, Civil Div., Dept of Justice; Spec Counsel, Ofc of Leg. Affairs, Dept of Justice; Counsel and LA, Senator Carol Moseley-Braun
Emily Murry
Staff Dir., Sub. Cmte. on Health, W&M Cmte; Sr. Policy Advisor, Majority Leader McCarthy; Policy Advisor, Majority Whip McCarthy; Professional Staff, Republican Study Cmte.; Leg. Aid, Rep. Ken Calvert; Leg. Asst., Rep. Tom Price
Raissa Downs TARPLI
Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte.
Kimberly Brandt
Sr. Counsel and Dir. External Affairs - HHS OIG; Prin. Dep. Administrator for Policy and Operations and Dir. of Medicare Program Integrity - CMS; Chief Oversight and General Counsel - Senate Cmte. on Finance
Margaret Joseph
CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte.
Peter Fise
Health Counsel for Sen. Cmte on Finance, Health Counsel for Sen. Jeanne Shaheen, Staff Assistant for House Cmte on Oversight & Government Reform
Laura Friedel
Leg. Asst., Sen. Zell Miller, Leg. Dir., Sen. Richard Shelby, Clerk, Staff Dir., Sen. Appropriations Committee
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on April 22.
Original Filing: 301570804.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
IRA implementation, pharmaceutical access and affordability, 340B, HCV screening, drug pricing and access, HIV, oncology, PAPHA reauthorization, transparency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2023
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Jan. 18.
Original Filing: 301527649.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
IRA implementation, pharmaceutical access and affordability, 340B, HCV screening, drug pricing and access, HIV, oncology, PAPHA reauthorization, transparency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2023
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Oct. 20, 2023.
Original Filing: 301515652.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
IRA implementation, pharmaceutical access and affordability, 340B, HCV screening, drug pricing and access, HIV, oncology, PAPHA reauthorization, transparency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2023
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on July 18, 2023.
Original Filing: 301479671.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
IRA implementation, pharmaceutical access and affordability, 340B, HCV screening, drug pricing and access, HIV, oncology, PAPHA reauthorization, transparency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2023
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on April 19, 2023.
Original Filing: 301459330.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
IRA implementation, pharmaceutical access and affordability, 340B, HCV screening, drug pricing and access, HIV, HCV, oncology
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Medicare & Medicaid payment and coverage issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2022
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Jan. 19, 2023.
Original Filing: 301434612.xml
Lobbying Issues
H.R.2617, Consolidated Appropriations Act, 2023
H.R. 5376, the Inflation Reduction Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5376, the Inflation Reduction Act
S. 4348, FDA Safety and Landmark Advancements Act
H.R. 7667, Food and Drug Amendments of 2022
H.R.2617, Consolidated Appropriations Act, 2023
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics, FDA user fees
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid, Pharmaceutical access & affordability, Part D benefit redesign, Hepatitis C, HIV, Coronavirus therapeutics, Medicaid Value Based Payment rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2022
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Oct. 19, 2022.
Original Filing: 301408833.xml
Lobbying Issues
H.R. 6833, Continuing Appropriations and Ukraine Supplemental Appropriations Act of 2023
H.R. 5376, the Inflation Reduction Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5376, the Inflation Reduction Act
S. 4348, FDA Safety and Landmark Advancements Act
H.R. 7667, Food and Drug Amendments of 2022
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics, FDA user fees
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid, Pharmaceutical access & affordability, Part D benefit redesign, Hepatitis C, HIV, Coronavirus therapeutics, Medicaid Value Based Payment rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2022
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on July 19, 2022.
Original Filing: 301386393.xml
Lobbying Issues
H.R. 5376, the Build Back Better Act
H.R. 2471, Consolidated Appropriations Act 2022
deficit reduction, reconciliation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5376, the Build Back Better Act
S. 4348, FDA Safety and Landmark Advancements Act
H.R. 7667, Food and Drug Amendments of 2022
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics, FDA user fees
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid, Pharmaceutical access & affordability, Part D benefit redesign, Hepatitis C, HIV, Coronavirus therapeutics, Medicaid Value Based Payment rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2022
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on April 20, 2022.
Original Filing: 301367277.xml
Lobbying Issues
deficit reduction, reconciliation
H.R. 5376, the Build Back Better Act
H.R. 2471, Consolidated Appropriations Act 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics
H.R. 5376, the Build Back Better Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Coronavirus therapeutics
Medicaid Value Based Payment rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2021
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Jan. 18, 2022.
Original Filing: 301325530.xml
Lobbying Issues
deficit reduction, reconciliation
H.R. 5376, the Build Back Better Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics
H.R. 5376, the Build Back Better Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Coronavirus therapeutics
Medicaid Value Based Payment rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2021
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Oct. 20, 2021.
Original Filing: 301310440.xml
Lobbying Issues
deficit reduction, reconciliation
S. Con. Res. 14
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics
S. 1260, U.S. Innovation and Competition Act of 2021
H.R. 1319, American Rescue Plan of 2021 implementation
H.R. 3, The Lower Drug Costs Now Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Coronavirus therapeutics
Medicaid Value Based Payment rule
H.R. 1319, American Rescue Plan of 2021 implementation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2021
TARPLIN, DOWNS & YOUNG, LLC amended a lobbying report for representation of Gilead Sciences, Inc. in Q32021 on Oct. 20, 2021.
Original Filing: 301313277.xml
Lobbying Issues
deficit reduction, reconciliation
S. Con. Res. 14
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics
H.R. 1319, American Rescue Plan of 2021 implementation
H.R. 3, The Lower Drug Costs Now Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Coronavirus therapeutics
Medicaid Value Based Payment rule
H.R. 1319, American Rescue Plan of 2021 implementation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2021
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on July 19, 2021.
Original Filing: 301283469.xml
Lobbying Issues
deficit reduction
S. Con. Res. 5 (117)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics
S. 1260, U.S. Innovation and Competition Act of 2021
H.R. 1319, American Rescue Plan of 2021 implementation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Coronavirus therapeutics
Medicaid Value Based Payment rule
H.R. 1319, American Rescue Plan of 2021 implementation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2021
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on April 19, 2021.
Original Filing: 301258047.xml
Lobbying Issues
deficit reduction
S. Con. Res. 5 (117)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics
H.R. 1319, The American Rescue Plan of 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Coronavirus therapeutics
Medicaid Value Based Payment rule
H.R. 1319, The American Rescue Plan of 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2020
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Jan. 19, 2021.
Original Filing: 301236978.xml
Lobbying Issues
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
H.R. 1865 - Further Consolidated Appropriations Act, 2020
H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act
H.R. 8337 - Continuing Appropriations Act of 2021
H.R. 133 - Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
HR 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
HR 6201 - Families First Coronavirus Response Act
S. 3548 - CARES Act
H.R. 6800 - The Heroes Act
H.R. 133 - Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
H.R. 259 - Medicaid Extenders Act of 2019
S. 3129 - Lower Costs, More Cures Act of 2019
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Coronavirus therapeutics
Medicaid Value Based Payment rule
H.R. 133 - Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2020
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Oct. 14, 2020.
Original Filing: 301209438.xml
Lobbying Issues
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
H.R. 1865 - Further Consolidated Appropriations Act, 2020
H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act
H.R. 8337 - Continuing Appropriations Act of 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
HR 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
HR 6201 - Families First Coronavirus Response Act
S. 3548 - CARES Act
H.R. 6800 - The Heroes Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
H.R. 259 - Medicaid Extenders Act of 2019
S. 3129 - Lower Costs, More Cures Act of 2019
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Coronavirus therapeutics
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2020
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on July 20, 2020.
Original Filing: 301194727.xml
Lobbying Issues
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
H.R. 1865 - Further Consolidated Appropriations Act, 2020
H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
HR 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
HR 6201 - Families First Coronavirus Response Act
S. 3548 - CARES Act
H.R. 6800 - The Heroes Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
H.R. 259 - Medicaid Extenders Act of 2019
S. 3129 - Lower Costs, More Cures Act of 2019
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Coronavirus therapeutics
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2020
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on April 19, 2020.
Original Filing: 301172159.xml
Lobbying Issues
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
H.R. 1865 - Further Consolidated Appropriations Act, 2020
H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
HR 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
HR 6201 - Families First Coronavirus Response Act
S. 3548 - CARES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
H.R. 259 - Medicaid Extenders Act of 2019
S. 3129 - Lower Costs, More Cures Act of 2019
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2019
In Q4, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Jan. 21, 2020.
Original Filing: 301127664.xml
Lobbying Issues
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
H.R. 1865 - Further Consolidated Appropriations Act, 2020
H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
H.R. 259 - Medicaid Extenders Act of 2019
S. 3129 - Lower Costs, More Cures Act of 2019
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2019
In Q3, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on Oct. 21, 2019.
Original Filing: 301074310.xml
Lobbying Issues
H.R. 2740 - HHS Appropriations, 2020
H.R. 3164 - FDA Appropriations, 2020
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology
S. 1416 - Affordable Prescriptions For Patients Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
H.R. 259 - Medicaid Extenders Act of 2019
Pharmaceutical access & affordability
Part D benefit redesign
Hepatitis C
HIV
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2019
In Q2, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on July 22, 2019.
Original Filing: 301057942.xml
Lobbying Issues
H.R. 2740 - HHS Appropriations, 2020
H.R. 3164 - FDA Appropriations, 2020
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology
S. 1416 - Affordable Prescriptions For Patients Act of 2019
S. 1895 - Lower Health Care Costs Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
H.R. 259 - Medicaid Extenders Act of 2019
Pharmaceutical access & affordability
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2019
In Q1, TARPLIN, DOWNS & YOUNG, LLC lobbied for Gilead Sciences, Inc. , earning $80,000. The report was filed on April 22, 2019.
Original Filing: 301034055.xml
Lobbying Issues
H.J.Res. 31 - Consolidated Appropriations Act, 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Six protected classes, Medicare Part D, HIV, Medicaid
H.R. 259 - Medicaid Extenders Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2019
Tarplin, Downs & Young, LLC filed a lobbying registration on Jan. 29, 2019 to represent Gilead Sciences, Inc., effective Jan. 1, 2019.
Original Filing: 301019204.xml
Issue(s) they said they’d lobby about: HIV, AIDS, 6 protected classes, Part D, Medicaid .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate